ArticleMediators of inflammation2026
Yiqi-Wenyang-Tiaoshen Decoction Reduces Cisplatin-Induced Acute Kidney Injury in Rats Through Autophagy and Apoptosis Signaling Pathways Based on Network Pharmacology and Experimental Validation.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
contextThe mechanism of Yiqi-Wenyang-Tiaoshen decoction (YWT) in treating cisplatin-induced acute kidney injury (AKI) remains unknown.
objectiveThis study identifies the key components of YWT and explores its therapeutic potential and mechanisms in a cisplatin-induced AKI rat model. MATERIALS AND
methodsUPLC-ESI-MS/MS was utilized for the identification of compounds present in both the aqueous extract of YWT and serum samples. The overlapping components were recognized as active constituents, followed by a network pharmacological analysis. A rat model of cisplatin-induced AKI was established, and comprehensive pathological analyses including HE, PAS, and electron microscopy, as well as biochemical assessments of serum Cre, BUN, IL-6, and TNF-α levels, were conducted. Western blotting was utilized to evaluate the expression levels of Caspase-3, Caspase-9, BAX, Bcl-2, and LC3 Ⅱ/Ⅰ.
resultsUsing UPLC-ESI-MS/MS, we identified 182 compounds in the aqueous extract of YWT, 34 of which are confirmed to be absorbable into the bloodstream. Network pharmacological analysis suggests that YWT primarily acts by inhibiting apoptosis and activating autophagy. In the rat model, YWT significantly ameliorated renal pathology and electron microscopic features. Additionally, YWT mitigated body weight loss and renal hypertrophy while lowering serum creatinine and blood urea nitrogen levels. YWT alleviates AKI by suppressing apoptosis-related proteins such as Caspase-3, Caspase-9, and BAX, enhancing Bcl-2 expression, increasing the LC3 Ⅱ/Ⅰ ratio, and reducing p62, a marker of autophagy. DISCUSSION AND
conclusionThis study confirms the therapeutic efficacy of YWT in cisplatin-induced AKI, potentially linked to its ability to inhibit apoptosis, activate autophagy, and mitigate mitochondrial damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.